Clinical Trial

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

Name: Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients — clinical trial record (NCT06463691)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a an open-label, multi-center, single-arm study to evaluate the efficacy and safety of sonrotoclax, zanubrutinib and CD20mab in untreated MCL patients.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-06-13.

Status change: Not Yet Recruiting → Recruiting 2025-05-08

Trial Details

NCT Number	NCT06463691
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	MCL
Enrollment	30 participants
Start Date	2024-08-01
Primary Completion	2028-12 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2025-05-11